On Oct 18, major Wall Street analysts update their ratings for $Intuitive Surgical (ISRG.US)$, with price targets ranging from $525 to $555.
Wells Fargo analyst Larry Biegelsen maintains with a buy rating, and adjusts the target price from $416 to $549.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Stifel analyst Rick Wise maintains with a buy rating, and adjusts the target price from $475 to $525.
BTIG analyst Ryan Zimmerman maintains with a buy rating, and adjusts the target price from $518 to $535.
RBC Capital analyst Shagun Singh Chadha maintains with a buy rating, and adjusts the target price from $525 to $555.
Furthermore, according to the comprehensive report, the opinions of $Intuitive Surgical (ISRG.US)$'s main analysts recently are as follows:
The expectation of a significant revenue outperformance for FY25 appears to be a prevailing sentiment. This perspective is reinforced by the company's recent quarterly report, which prompted a revision of the estimated earnings per share for FY25, increasing it approximately by 3%.
Intuitive Surgical registered 'strong' results for Q3, particularly excelling in the two most vital metrics—DV5 placements and procedure growth. Seven months post the U.S. approval of da Vinci 5, Intuitive Surgical is experiencing significant post-launch growth momentum. The early adoption of DV5 is surpassing the initial uptake of the fourth-generation system, indicating a promising potential for accelerated growth as we look towards 2025.
The company's Q3 earnings and revenue exceeded expectations, accompanied by a procedure volume growth of 18% which also surpassed the consensus by 100bps. With a series of regulatory approvals for Dv5, it is anticipated that the growth momentum of Dv5 will be maintained, even as it enters into a wider release in the second half of FY25.
The conviction in the sustained upward potential of Intuitive Surgical strengthens, supporting its premium valuation. It stands out as a top-tier long-term growth prospect following the company's performance that surpassed estimates and showcased accelerated growth across various metrics.
Here are the latest investment ratings and price targets for $Intuitive Surgical (ISRG.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月18日，多家華爾街大行更新了$直覺外科公司 (ISRG.US)$的評級，目標價介於525美元至555美元。
富國集團分析師Larry Biegelsen維持買入評級，並將目標價從416美元上調至549美元。
奧本海默控股分析師Suraj Kalia維持持有評級。
斯迪富分析師Rick Wise維持買入評級，並將目標價從475美元上調至525美元。
BTIG分析師Ryan Zimmerman維持買入評級，並將目標價從518美元上調至535美元。
加皇資本市場分析師Shagun Singh Chadha維持買入評級，並將目標價從525美元上調至555美元。
此外，綜合報道，$直覺外科公司 (ISRG.US)$近期主要分析師觀點如下：
對於FY25來說，有望實現顯著的營業收入表現似乎是一種普遍情緒。這一觀點得到了公司最近季度報告的支持，導致了對FY25預計每股收益的修訂，預計將增加約3%。
直覺外科公司在Q3取得了「強勁」的成績，尤其在兩個最關鍵的指標——DV5設備放置和手術量增長方面表現出色。美國批准達芬奇5後的七個月，直覺外科公司正在經歷顯著的發佈後增長勢頭。DV5的早期採用超越了第四代系統的初期接受程度，顯示出2025年加速增長的潛力。
該公司Q3的收益和營業收入超出了預期，手術量增長18%，也比共識高出100個點子。隨着Dv5獲得一系列監管批准，預計Dv5的增長勢頭將得以維持，即使在FY25下半年開始更廣泛的發佈。
對直覺外科公司持續向上潛力的信念增強，支撐其高溢價估值。在公司的表現超過預期並展示出各種指標加速增長之後，它成爲長期增長前景中的優秀選擇。
以下爲今日7位分析師對$直覺外科公司 (ISRG.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
